Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Guangdong Association of Clinical Trials
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Duke University
Charite University, Berlin, Germany
M.D. Anderson Cancer Center
Aarhus University Hospital
Northwestern University
University of Miami
University of Miami
Nationwide Children's Hospital
Brazilian Clinical Research Institute
M.D. Anderson Cancer Center
Boston Medical Center
Duke University
Ottawa Hospital Research Institute
New York University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Turin, Italy
Memorial Sloan Kettering Cancer Center
Ottawa Hospital Research Institute
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Brigham and Women's Hospital
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Mario Negri Institute for Pharmacological Research
London School of Hygiene and Tropical Medicine
National Taiwan University Hospital
Peking University First Hospital
Affiliated Cancer Hospital of Shantou University Medical College
European Institute of Oncology
University of Iowa
Ain Shams University
University of Washington
University of Washington
Tampere University
Biotech Pharmaceutical Co., Ltd.
University Hospital, Strasbourg, France
Peking Union Medical College Hospital
St. Luke's Hospital, Pennsylvania
Institut Sainte Catherine
Udayana University
University Hospital Dubrava
Monash University
Chiayi Christian Hospital
Chiayi Christian Hospital
Chang Gung Memorial Hospital
University Hospital Virgen de las Nieves
ShuGuang Hospital